• 下载App


  • 在线客服

成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Announces Uplist to the OTCQB(R) Venture Market
CB Science,Inc.宣布进入OTCQB(注册商标)风险市场

Accesswire ·  {{timeTz}}

Shareholders to benefit from greater transparency and improved liquidity


ESCONDIDO, CA / ACCESSWIRE / April 6, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). The Company will commence trading on the OTCQB with the market open on April 6, 2022, under the symbol "CBSC."

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2022年4月6日/CB Science。无创动态心脏监护仪产品和服务的设计商、制造商和分销商CBSC公司(以下简称“CBSC”或“公司”)今天宣布,该公司成功地从场外交易粉单上升到场外交易®创业板市场(以下简称“OTCQB”)。该公司将于2022年4月6日在场外交易市场开始交易,交易代码为“CBSC”。

"Trading on OTCQB is an important achievement for our Company, providing increased transparency and improved liquidity to both existing and prospective shareholders," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "In combination with plans underway for ongoing corporate growth through the balance of the year, we believe listing on the OTCQB will allow our story to reach a wider investor audience, a key objective for the Company in 2022."

CB Science公司首席执行官查尔斯·马丁说:“在场外交易市场进行交易是我们公司的一项重要成就,为现有股东和潜在股东提供了更高的透明度和更好的流动性。”结合今年剩余时间公司持续增长的计划,我们相信在OTCQB上市将使我们的故事接触到更广泛的投资者受众,这是公司2022年的关键目标。

OTCQB is operated by OTC Markets Group, Inc. and is designed for early-stage and developing companies in the United States and abroad. To be eligible for OTCQB quotes, companies must be current in their disclosure filings, have audited financial statements, and undergo an annual validation and management certification process. Companies must also meet minimum bid testing and other financial terms. OTCQB is recognized as an established public market by the Securities and Exchange Commission ("SEC") and provides current public information to investors in need of securities analysis, valuation, and trading.

OTCQB由OTC Markets Group,Inc.运营,专为美国和海外处于早期阶段和发展中的公司而设计。要有资格获得OTCQB报价,公司必须在其披露文件中保持最新,已审计财务报表,并经历年度验证和管理认证过程。公司还必须满足最低投标测试和其他财务条款。场外交易市场被美国证券交易委员会(“美国证券交易委员会”)认可为成熟的公开市场,为需要进行证券分析、估值和交易的投资者提供最新的公开信息。

"Realizing this significant accomplishment represents another major milestone in the Company's pursuit of planned business objectives," said Paul Danner, Chairman of CB Scientific, Inc. "We are now positioned to move forward with our plans to implement a corporate name change which more accurately describes our business direction and future growth potential, and relocation of our corporate domicile to Nevada which provides superior tax laws and corporate regulations."

CB Science,Inc.董事长保罗·丹纳说:“实现这一重大成就代表着公司追求计划中的业务目标的又一个重要里程碑。我们现在准备推进我们的计划,实施公司更名,更准确地描述我们的业务方向和未来的增长潜力,并将我们的公司注册地迁往内华达州,这将提供更好的税法和公司法规。“

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,让其股东、行业参与者和公开市场了解情况。

About CB Scientific, Inc.

关于CB Science,Inc.

CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

CB Science,Inc.通过其国内和国际子公司,在动态非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件和适用于iOS和Android平台的智能手机应用程序为有异常心律风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:


Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电子邮件:General Query:Info@cbScience ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.


SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.

View source version on accesswire.com: